## Real-world data

## **GORE® TAG®**

Conformable Thoracic Stent Graft with ACTIVE CONTROL System



SURPASS\* is an observational, prospective, single-arm post-market registry. 20 European sites in seven countries are included.

## ZERO 100% 98.4%

- Type Ia and Type III endoleaks
- Fractures
- Device compressions
- Ruptures


Successful deployment

With no device-related issues

Freedom from serious access complications

## Aortic pathology treated:

- Treatment of Type B dissection (complicated / uncomplicated)
- Descending thoracic aortic aneurysms (Including ruptures)
- Penetrating aortic ulcers
- Traumatic aortic transection
- Intramural hematoma
- Pseudoaneurysm



98.4%

Reported that proximal wall apposition was acceptable at procedural completion

1.38

Devices per procedure

92.9%

No rapid pacing used

Consult Instructions for Use eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® TAG® Conformable Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: isolated lesions in patients who have appropriate anatomy, including: adequate iliac/femoral access, aortic inner diameter in the range of 16-42 mm, ≥ 20 mm nonaneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac/femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16-42 mm. CONTRAINDICATIONS: Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. R<sub>X Only</sub> INDICATIONS FOR USE UNDER CE MARK: The GORE® TAG® Conformable Thoracic Stent Graft is indicated for endovascular repair of all lesions of the descending thoracic aorta, including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections. CONTRAINDICATIONS: Patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. R<sub>x Only</sub>

Products listed may not be available in all markets.

GORE, Together, improving life, ACTIVE CONTROL, TAG and designs are trademarks of W. L. Gore & Associates. © 2019, 2022 W. L. Gore & Associates, Inc. 22618259-EN JULY 2022

W. L. Gore & Associates, Inc.

goremedical.com



<sup>\*</sup> Rates are based on physician experience as reported for 127 subjects in Europe within a 30 day follow-up period. European-Post Approval Registry: Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System. (data on file 2017; W.L. Gore & Associates, Inc; Flagstaff, AZ.)